Reported 1 day ago
In May 2024, Jim Cramer expressed confidence in Moderna, Inc. (NASDAQ:MRNA), recalling its rise to $400 and sharing plans to invest when it was around $130. However, the stock has since plummeted by 81.28% over the past year, and Cramer later pointed to various struggles the company faced, including controversies and a potential halt to its personalized cancer vaccine initiatives. Despite acknowledging MRNA's growth potential, the article suggests that other AI stocks may offer better returns with less risk.
Source: YAHOO